C. Soulié

发表

Presence of HIV-1 R5 Viruses in Cerebrospinal Fluid Even in Patients Harboring R5X4/X4 Viruses in Plasma

V. Calvez, R. Tubiana, C. Katlama, 2009, Journal of acquired immune deficiency syndromes.

Les tests de tropisme du VIH à l’heure de la mise à disposition du 1er anti-CCR5

V. Calvez, C. Soulié, 2008 .

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc

V. Calvez, C. Charpentier, J. Pawlotsky, 2015, PloS one.

Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study

C. Charpentier, B. Masquelier, J. Izopet, 2010, Antimicrobial Agents and Chemotherapy.

Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2020, The Journal of antimicrobial chemotherapy.

Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2018, The Journal of antimicrobial chemotherapy.

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.

V. Calvez, C. Katlama, O. Delelis, 2009, The Journal of antimicrobial chemotherapy.

Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS‐163 ETRAL Study

V. Calvez, C. Katlama, Y. Yazdanpanah, 2019, Pharmacotherapy.

Comparison of two genotypic algorithms to determine HIV‐1 tropism *

V. Calvez, G. Carcelain, C. Katlama, 2008, HIV medicine.

Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes

V. Calvez, C. Katlama, O. Delelis, 2009, Antiviral therapy.

The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients

V. Calvez, C. Charpentier, D. Boutolleau, 2021, Journal of Infection.

Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries

V. Calvez, F. Brun-Vézinet, M. Peeters, 2018, The Journal of antimicrobial chemotherapy.

Comparison of HIV-Infected and Noninfected Patients Undergoing Bariatric Surgery: The ObeVIH Study

C. Katlama, D. Costagliola, J. Capeau, 2022, Journal of acquired immune deficiency syndromes.

Memory CD4+ T-Cell Lymphocytic Angiopathy in Fatal Forms of COVID-19 Pulmonary Infection

B. Autran, P. Debré, D. Seilhean, 2022, Frontiers in Immunology.

High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.

V. Calvez, O. Koita, M. Sylla, 2014, The Journal of antimicrobial chemotherapy.

A Very Low Geno2pheno False Positive Rate Is Associated with Poor Viro-Immunological Response in Drug-Naïve Patients Starting a First-Line HAART

V. Calvez, F. Ceccherini‐Silberstein, A. Antinori, 2014, PloS one.

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.

V. Calvez, C. Charpentier, B. Masquelier, 2013, The Journal of antimicrobial chemotherapy.

Circulating Interleukin-6 Levels Correlate with Residual HIV Viraemia and Markers of Immune Dysfunction in Treatment-Controlled HIV-Infected Patients

V. Calvez, C. Katlama, J. Capeau, 2012, Antiviral therapy.

Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia

V. Calvez, G. Carcelain, C. Katlama, 2016, AIDS.

HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs.

V. Calvez, G. Carcelain, C. Katlama, 2012, The Journal of antimicrobial chemotherapy.

High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2

V. Calvez, R. Tubiana, D. Klatzmann, 2022 .

High seroconversion rate and SARS-CoV-2 Delta neutralization in PLWHIV vaccinated with BNT162b2

V. Calvez, R. Tubiana, D. Klatzmann, 2021 .

Authors’ Reply

J. Capeau, J. Bastard, A. Marcelin, 2013 .

Routine screening for HIV, hepatitis B virus and hepatitis C virus in individuals undergoing oral and maxillofacial surgery

C. Katlama, P. Coriat, D. Costagliola, 2019, HIV medicine.

Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia

C. Katlama, B. Autran, D. Costagliola, 2015, AIDS (London).

No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments.

V. Calvez, R. Tubiana, C. Katlama, 2021, The Journal of antimicrobial chemotherapy.

Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma

V. Calvez, C. Delaugerre, S. Yerly, 2017, The Journal of antimicrobial chemotherapy.

Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.

V. Calvez, C. Charpentier, C. Katlama, 2016, The Journal of antimicrobial chemotherapy.

Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.

V. Calvez, C. Charpentier, C. Katlama, 2015, AIDS research and human retroviruses.

Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.

C. Katlama, D. Costagliola, G. Peytavin, 2014, The Journal of antimicrobial chemotherapy.

Upgraded Cobas Ampliprep-Cobas TaqMan Version 2.0 HIV-1 RNA Quantification Assay versus First Version: Correction of Underestimations

V. Calvez, R. Tubiana, C. Katlama, 2011, Journal of Clinical Microbiology.

Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia.

V. Calvez, C. Katlama, M. Valantin, 2011, The Journal of antimicrobial chemotherapy.

Underestimations versus First Version : Correction of AssayVersion 2 . 0 HIV-1 RNA Quantification Upgraded Cobas Ampliprep-Cobas TaqMan

R. Tubiana, S. Fourati, C. Soulié, 2011 .

Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma.

V. Calvez, C. Delaugerre, S. Yerly, 2015, The Journal of antimicrobial chemotherapy.

Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer

A. Samri, C. Katlama, B. Autran, 2022, Cells.

Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score

V. Calvez, R. Tubiana, C. Katlama, 2014, Infection.

The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients

V. Calvez, C. Charpentier, S. Burrel, 2021, Journal of Infection.

Performance of genotypic algorithms for predicting tropism of HIV-1CRF02_AG subtype.

V. Calvez, C. Katlama, P. Girard, 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Virological failure of patients on maraviroc-based antiretroviral therapy.

C. Delaugerre, J. Izopet, P. Bellecave, 2015, The Journal of antimicrobial chemotherapy.

Replicationd Patients with Ongoing HIV-1 Dynamics and Coreceptor Usage in

V. Calvez, P. Harrigan, H. Fleury, 2014 .

Replication Maraviroc-Treated Patients with Ongoing HIV-1 Dynamics and Coreceptor Usage in

V. Calvez, P. Harrigan, H. Fleury, 2013 .

HIV-1 Dynamics and Coreceptor Usage in Maraviroc-Treated Patients with Ongoing Replication

V. Calvez, P. Harrigan, B. Masquelier, 2012, Antimicrobial Agents and Chemotherapy.

Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in

V. Calvez, C. Katlama, D. Costagliola, 2009, AIDS.

Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer.

A. Samri, B. Autran, J. Spano, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B.

V. Calvez, C. Katlama, S. Fourati, 2013, The Journal of antimicrobial chemotherapy.

Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area

R. Tubiana, C. Katlama, D. Costagliola, 2022, European Journal of Clinical Microbiology & Infectious Diseases.

Effect of antiretroviral drugs on the quality of semen

V. Calvez, R. Tubiana, G. Peytavin, 2011, Journal of medical virology.

Co-infection of SARS-CoV-2 with other respiratory viruses and performance of lower respiratory tract samples for the diagnosis of COVID-19

V. Calvez, D. Boutolleau, S. Burrel, 2020, International Journal of Infectious Diseases.

Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients

D. Thabut, S. Varnous, F. Conti, 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

Sialolithiasis in an HIV-1-infected patient treated with atazanavir/ritonavir monotherapy.

C. Katlama, M. Lê, G. Peytavin, 2013, The Journal of antimicrobial chemotherapy.

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

Luba Tchertanov, Vincent Calvez, Christine Katlama, 2008, Antimicrobial Agents and Chemotherapy.

Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.

V. Calvez, C. Katlama, D. Costagliola, 2008, The Journal of antimicrobial chemotherapy.

Pharmacokinetics, protein‐binding‐adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment‐naïve HIV‐infected patients *

V. Calvez, C. Katlama, G. Peytavin, 2010, HIV medicine.

Resistance profile and treatment outcomes in HIV-infected children at virological failure in Benin, West Africa

G. Peytavin, P. Girard, L. Morand‐Joubert, 2018, The Journal of antimicrobial chemotherapy.

Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?

V. Calvez, C. Charpentier, C. Delaugerre, 2019, The Journal of antimicrobial chemotherapy.

No HIV-1 molecular evolution on long term antiretroviral therapy initiated during primary HIV-1 infection.

V. Calvez, R. Tubiana, C. Katlama, 2020, AIDS.

Coreceptor usage in different reservoirs

V. Calvez, A. Marcelin, C. Soulié, 2012, Current opinion in HIV and AIDS.

Evolution of viral quasispecies during SARS-CoV-2 infection

V. Calvez, D. Boutolleau, S. Burrel, 2020, Clinical Microbiology and Infection.

Prevalence of HIV-1 Natural Polymorphisms and Integrase-Resistance-Associated Mutations in African Children

V. Calvez, C. Katlama, R. Murphy, 2023, Viruses.

Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy

C. Charpentier, L. Cuzin, M. Guiguet, 2015, AIDS.

Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2

F. Carrat, R. Liblau, G. Martin-Blondel, 2022, Journal of Infection.

Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study)

F. Carrat, R. Liblau, G. Martin-Blondel, 2022, Journal of Infection.

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy.

V. Calvez, G. Carcelain, R. Tubiana, 2014, The Journal of antimicrobial chemotherapy.

Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.

V. Calvez, R. Tubiana, L. Mandelbrot, 2015, Antiviral therapy.

Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.

C. Katlama, D. Costagliola, E. Martinez, 2019, The Journal of antimicrobial chemotherapy.

Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).

V. Calvez, D. Podzamczer, C. Delaugerre, 2020, The Journal of antimicrobial chemotherapy.

Birth Country Influences the Choice of Antiretroviral Therapy in HIV-Infected Individuals: Experience From a French HIV Centre

R. Tubiana, C. Katlama, L. Cuzin, 2022, Journal of acquired immune deficiency syndromes.

Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies

V. Calvez, S. Choquet, M. Dres, 2022, Viruses.

E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations.

V. Calvez, C. Katlama, S. Benichou, 2012, Antiviral research.

V. Calvez, C. Katlama, B. Masquelier, 2012, PloS one.

Positive Impact of HIV-1 gag Cleavage Site Mutations on the Virological Response to Darunavir Boosted with Ritonavir

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2011, Antimicrobial Agents and Chemotherapy.

Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations.

V. Calvez, R. Tubiana, C. Katlama, 2020, The Journal of antimicrobial chemotherapy.

Long-term evolution of humoral immune response after SARS-CoV-2 infection

F. Tubach, D. Boutolleau, B. Abdi, 2022, Clinical Microbiology and Infection.

Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.

V. Calvez, C. Charpentier, P. Bellecave, 2021, The Journal of antimicrobial chemotherapy.

Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.

V. Calvez, C. Charpentier, B. Masquelier, 2014, The Journal of antimicrobial chemotherapy.

E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure

V. Calvez, C. Katlama, S. Fourati, 2012, AIDS.

Long-term follow-up of HIV-infected patients on dolutegravir monotherapy.

R. Tubiana, C. Katlama, G. Peytavin, 2019, The Journal of antimicrobial chemotherapy.

Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia.

V. Calvez, R. Tubiana, C. Katlama, 2016, The Journal of antimicrobial chemotherapy.

Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study)

V. Calvez, C. Charpentier, C. Delaugerre, 2018, The Journal of antimicrobial chemotherapy.

Kinetics of archived M184V mutation in treatment-experienced virally suppressed HIV-infected patients.

V. Calvez, R. Tubiana, C. Katlama, 2021, The Journal of infectious diseases.

Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study.

R. Tubiana, C. Katlama, G. Peytavin, 2019, The Journal of antimicrobial chemotherapy.

Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey

V. Calvez, C. Delaugerre, C. Katlama, 2007, AIDS.

Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART

V. Calvez, C. Katlama, M. Valantin, 2018, The Journal of antimicrobial chemotherapy.

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Presence of HIV-1 G-to-A mutations linked to APOBEC editing is more prevalent in non-B HIV-1 subtypes and is associated with lower HIV-1 reservoir.

V. Calvez, R. Tubiana, C. Katlama, 2021, The Journal of antimicrobial chemotherapy.

Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).

V. Calvez, C. Katlama, D. Costagliola, 2015, The Journal of antimicrobial chemotherapy.

Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.

V. Calvez, C. Charpentier, C. Katlama, 2021, The Journal of antimicrobial chemotherapy.

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.

V. Calvez, R. Tubiana, C. Katlama, 2010, The Journal of antimicrobial chemotherapy.

Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years

V. Calvez, R. Tubiana, C. Katlama, 2011, AIDS.

HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART

V. Calvez, C. Katlama, D. Costagliola, 2007, AIDS.

Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir

Philippe Flandre, Vincent Calvez, Christine Katlama, 2007, Antimicrobial Agents and Chemotherapy.

Identification of natural killer markers associated with fatal outcome in COVID-19 patients

A. Samri, N. Tarantino, Z. Amoura, 2023, Frontiers in Cellular and Infection Microbiology.

Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study.

V. Calvez, C. Katlama, M. Lê, 2015, The Journal of antimicrobial chemotherapy.

Raltegravir Concentrations in the Genital Tract of HIV-1-Infected Women Treated with a Raltegravir-Containing Regimen (DIVA 01 Study)

R. Tubiana, C. Katlama, L. Mandelbrot, 2011, Antimicrobial Agents and Chemotherapy.

Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.

V. Calvez, C. Charpentier, C. Delaugerre, 2012, The Journal of antimicrobial chemotherapy.

Etravirine Concentrations in the Cervicovaginal Compartment in HIV-1-Infected Women Receiving Etravirine-Containing Antiretroviral Therapy: DIVA 02 Study

R. Tubiana, C. Katlama, L. Mandelbrot, 2012, Antimicrobial Agents and Chemotherapy.

Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes.

V. Calvez, C. Charpentier, C. Katlama, 2015, The Journal of antimicrobial chemotherapy.

Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers

V. Calvez, J. Pawlotsky, D. Boutolleau, 2021, Clinical Infectious Diseases.

Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers

V. Calvez, J. Pawlotsky, D. Boutolleau, 2021, bioRxiv.

Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir

F. Carrat, R. Liblau, G. Martin-Blondel, 2022, Clinical Microbiology and Infection.

HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis

V. Calvez, R. Tubiana, C. Katlama, 2010, AIDS (London).

Poor Antibody Response after Two Doses of SARS-CoV-2 vaccine in Transplant Recipients.

D. Thabut, F. Conti, B. Barrou, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

High SARS-CoV-2 seroprevalence in HIV patients originating from sub-Saharan Africa in the Ile-de-France area

V. Calvez, R. Tubiana, C. Katlama, 2022, Journal of Infection.

Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.

V. Calvez, R. Tubiana, C. Katlama, 2008, The Journal of antimicrobial chemotherapy.

Discovery, SAR study and ADME properties of methyl 4-amino-3-cyano-1-(2-benzyloxyphenyl)-1H-pyrazole-5-carboxylate as an HIV-1 replication inhibitor.

V. Calvez, O. Delelis, S. Priet, 2020, RSC medicinal chemistry.

Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B.

V. Calvez, H. Traoré, S. Fourati, 2013, The Journal of antimicrobial chemotherapy.

Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients

F. Carrat, O. Schwartz, S. Munier, 2023, medRxiv.

Prolonged replication of BA.1 and BA.2 Omicron lineages compared to Delta variant in nasopharyngeal samples from COVID-19 patients

V. Calvez, B. Abdi, E. Teyssou, 2022, Infectious Diseases Now.

Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen

V. Calvez, C. Charpentier, P. André, 2018, The Journal of antimicrobial chemotherapy.

Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia

R. Tubiana, C. Katlama, M. Lê, 2018, The Journal of antimicrobial chemotherapy.

Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?

C. Louapre, E. Maillart, B. Abdi, 2023, Journal of neurology, neurosurgery, and psychiatry.

Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm3 at the time of diagnosis according to HIV‐1 coreceptor tropism

V. Calvez, C. Charpentier, G. Carcelain, 2012, Journal of Medical Virology.

Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.

R. Tubiana, C. Katlama, F. Raffi, 2020, The Journal of antimicrobial chemotherapy.

Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV

R. Tubiana, C. Katlama, L. Schneider, 2023, Journal of personalized medicine.

Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients.

V. Calvez, R. Tubiana, C. Katlama, 2021, The Journal of antimicrobial chemotherapy.

C. Katlama, D. Costagliola, E. Martinez, 2020, The Journal of antimicrobial chemotherapy.

Structural effects of amino acid variations between B and CRF02‐AG HIV‐1 integrases

O. Traoré, V. Calvez, C. Katlama, 2008, Journal of medical virology.

Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients

V. Calvez, R. Tubiana, C. Katlama, 2008, AIDS.

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

V. Calvez, C. Katlama, O. Delelis, 2008, Antimicrobial Agents and Chemotherapy.

V. Calvez, C. Katlama, D. Costagliola, 2008, Journal of Antimicrobial Chemotherapy.

Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years

V. Calvez, R. Tubiana, C. Katlama, 2011, AIDS.

SARS-CoV-2 variant-dependent inflammasome activation

V. Calvez, V. Leducq, E. Teyssou, 2023, Journal of Infection.

Pharmacokinetics of high dosage of linezolid in two morbidly obese patients.

V. Calvez, C. Katlama, V. Ranieri, 2015, The Journal of antimicrobial chemotherapy.

Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm3 at the time of diagnosis according to HIV‐1 coreceptor tropism

V. Calvez, C. Charpentier, G. Carcelain, 2012, Journal of medical virology.

High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2

V. Calvez, R. Tubiana, D. Klatzmann, 2022, AIDS.